PERSISTENCE WITH FINGOLIMOD VERSUS DIMETHYL FUMARATE IN PATIENTS WITH MULTIPLE SCLEROSIS: RETROSPECTIVE ANA LYSIS OF US OPEN-SOURCE PHARMACY DATA

被引：3
|
作者：
Bergvall, N. [1 ]
Lahoz, R. [1 ]
Nazareth, T. [2 ]
Korn, J. R. [3 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] IMS Hlth, Waltham, MA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.912
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：A400 / A400
页数：1
相关论文
共 50 条
  • [1] Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of US open source pharmacy data
    Bergvall, N.
    Lahoz, R.
    Nazareth, T.
    Korn, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 196 - 196
  • [2] Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
    Vollmer, Brandi L.
    Nair, Kavita V.
    Sillau, Stefan
    Corboy, John R.
    Vollmer, Timothy
    Alvarez, Enrique
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (02): : 252 - 262
  • [3] Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
    Vollmer, Brandi L.
    Nair, Kavita
    Sillau, Stefan
    Corboy, John R.
    Vollmer, Timothy
    Alvarez, Enrique
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (09): : 1466 - 1476
  • [4] Comparative effectiveness, persistence, and adherence of dimethyl fumarate and fingolimod in patients with multiple sclerosis in Japan: A cohort study
    Shimazaki, Sho
    Fukasawa, Toshiki
    Kondo, Takayuki
    Takeuchi, Masato
    Okura, Takayuki
    Takahashi, Ryosuke
    Kawakami, Koji
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 94
  • [5] FACTORS ASSOCIATED WITH PRESCRIBING OF TERIFLUNOMIDE AND DIMETHYL FUMARATE VERSUS FINGOLIMOD IN MULTIPLE SCLEROSIS
    Earla, J. r
    Hutton, G. J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2022, 25 (07) : S482 - S482
  • [6] Predicting the efficacy of fingolimod versus dimethyl fumarate in patients with multiple sclerosis using a statistical modelling approach
    Bergvall, N.
    Nixon, R.
    Tomic, D.
    Sfikas, N.
    Cutter, G.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 519 - 520
  • [7] PERSISTENCE IN OPEN AND CLOSED DATA SOURCES: A STUDY OF FINGOLIMOD VERSUS INTERFERONS/GLATIRAMER ACETATE IN PATIENTS WITH MULTIPLE SCLEROSIS
    Lahoz, R.
    Bergvall, N.
    Nazareth, T.
    Korn, J. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A401
  • [8] Early versus delayed initiation of fingolimod or dimethyl fumarate in relapsing-remitting multiple sclerosis
    Lorscheider, J.
    Schadelin, S.
    Benkert, P.
    Lienert, C.
    Hanni, P.
    Derfuss, T.
    Decard, B.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 257 - 258
  • [9] Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
    Tanaka, Eizo
    Watanabe, Mitsuru
    Fukumoto, Shoko
    Masaki, Katsuhisa
    Yamasaki, Ryo
    Matsushita, Takuya
    Isobe, Noriko
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [10] Increased Multiple Sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate
    Delgado, Silvia
    Hernandez, Jeffrey
    Tornes, Leticia
    Rammohan, Kottil
    NEUROLOGY, 2019, 92 (15)
12345